共 244 条
[1]
Robillard L(2017)In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib Cancer Res 103 334-346
[2]
Nguyen M(2011)Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated J Natl Cancer Inst 8 107-118
[3]
Harding TC(2019) or Clin Pharmacol Drug Dev 23 4095-4106
[4]
Simmons AD(2017)Pharmacokinetic study of rucaparib in patients with advanced solid tumors Clin Cancer Res 50 1032-1042
[5]
Drew Y(2020)A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors Xenobiotica 17 65-82
[6]
Mulligan EA(2015)Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor AAPS J 43 490-509
[7]
Vong WT(2015)Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport–an update Drug Metab Dispos 12 58-65
[8]
Thomas HD(2019)Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design Clin Transl Sci 45 228-247
[9]
Kahn S(2009)Evaluation of drug–drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor Eur J Cancer 94 23-26
[10]
Kyle S(2013)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Clin Pharmacol Ther 20 109-117